CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 89 enrolled
Drug / intervention
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination +1 moredrug
Likely dose
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination 360 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03539900
NCT03539900Phase 3Completed
CompareCT.gov

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Yale University·interventional·Posted May 29, 2018·Updated Apr 3, 2024

In Brief

A Phase 3 clinical trial evaluating Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination and Placebo for Binge-Eating Disorder. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This study will test the efficacy of naltrexone HCI and bupropion HCI (NB) versus placebo in patients with binge-eating disorder (BED), with or without obesity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge-Eating Disorder
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 29, 2018
Enrollment StartApr 17, 2018
Primary CompletionApr 19, 2022
Study CompletionMar 22, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.1 years ago

Interventions

Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combinationdrug

NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.

Placeboother

Placebo will be inactive and taken daily in pill form.